The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

CK-0802 is under clinical development by Cellenkos and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

The risk of developing RDS was significantly increased among newborns born to mothers with confirmed COVID-19 infection during pregnancy.

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

Acute respiratory distress syndrome (ARDS) is a neutrophil-dominant disorder with no effective pharmacological therapies. While the cyclin-dependent kinase inhibitor AT7519 induces neutrophil ...

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

To establish a prediction nomogram for early prediction of neonatal acute respiratory distress syndrome (NARDS). Methods: This is a retrospective cross-sectional study conducted between January 2021 ...

Again, of the patients that died prior to hospital discharge, only one had a medical death certificate where ARDS was specified as a contributing cause of death, with many others (48%) recording ...